Cargando…

Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC)

Recently, immunotherapy has been shown to be an effective and helpful therapeutic option for the treatment of advanced non-small-cell lung cancer (NSCLC). The activity of antitumor T cells may be restored through the checkpoint blockade using anti-programmed death 1 or anti-programmed death ligand 1...

Descripción completa

Detalles Bibliográficos
Autores principales:	Incorvaia, Lorena, Fanale, Daniele, Badalamenti, Giuseppe, Barraco, Nadia, Bono, Marco, Corsini, Lidia Rita, Galvano, Antonio, Gristina, Valerio, Listì, Angela, Vieni, Salvatore, Gori, Stefania, Bazan, Viviana, Russo, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6822831/ https://www.ncbi.nlm.nih.gov/pubmed/31432460 http://dx.doi.org/10.1007/s12325-019-01057-7

Ejemplares similares

Prognostic role of soluble PD-1 and BTN2A1 in overweight melanoma patients treated with nivolumab or pembrolizumab: finding the missing links in the symbiotic immune-metabolic interplay
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Are Long Noncoding RNAs New Potential Biomarkers in Gastrointestinal Stromal Tumors (GISTs)? The Role of H19 and MALAT1
por: Badalamenti, Giuseppe, et al.
Publicado: (2019)

Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2
por: Fanale, Daniele, et al.
Publicado: (2020)

Is there any place for PD-1/CTLA-4 inhibitors combination in the first-line treatment of advanced NSCLC?—a trial-level meta-analysis in PD-L1 selected subgroups
por: Passiglia, Francesco, et al.
Publicado: (2021)

Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study
por: Gristina, Valerio, et al.
Publicado: (2022)

A “Lymphocyte MicroRNA Signature” as Predictive Biomarker of Immunotherapy Response and Plasma PD-1/PD-L1 Expression Levels in Patients with Metastatic Renal Cell Carcinoma: Pointing towards Epigenetic Reprogramming
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Prognostic Role of Plasma PD-1, PD-L1, pan-BTN3As and BTN3A1 in Patients Affected by Metastatic Gastrointestinal Stromal Tumors: Can Immune Checkpoints Act as a Sentinel for Short-Term Survival?
por: Fanale, Daniele, et al.
Publicado: (2021)

Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)—Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes
por: Incorvaia, Lorena, et al.
Publicado: (2020)

BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients
por: Incorvaia, Lorena, et al.
Publicado: (2020)

PD-L1 expression as predictive biomarker in patients with NSCLC: a pooled analysis
por: Passiglia, Francesco, et al.
Publicado: (2016)

The diagnostic accuracy of PIK3CA mutations by circulating tumor DNA in breast cancer: an individual patient data meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2022)

Monitoring blood biomarkers to predict nivolumab effectiveness in NSCLC patients
por: Passiglia, Francesco, et al.
Publicado: (2019)

Triple negative breast cancer: shedding light onto the role of pi3k/akt/mtor pathway
por: Massihnia, Daniela, et al.
Publicado: (2016)

Can the plasma PD-1 levels predict the presence and efficiency of tumor-infiltrating lymphocytes in patients with metastatic melanoma?
por: Incorvaia, Lorena, et al.
Publicado: (2019)

The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors
por: Dimino, Alessandra, et al.
Publicado: (2022)

Publisher Correction: The diagnostic accuracy of circulating tumor DNA for the detection of EGFR-T790M mutation in NSCLC: a systematic review and meta-analysis
por: Passiglia, Francesco, et al.
Publicado: (2018)

Moving the Target on the Optimal Adjuvant Strategy for Resected Pancreatic Cancers: A Systematic Review with Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2020)

Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs)
por: Incorvaia, Lorena, et al.
Publicado: (2021)

Is there any room for PD-1 inhibitors in combination with platinum-based chemotherapy as frontline treatment of extensive-stage small cell lung cancer? A systematic review and meta-analysis with indirect comparisons among subgroups and landmark survival analyses
por: Gristina, Valerio, et al.
Publicado: (2021)

Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions
por: Incorvaia, Lorena, et al.
Publicado: (2020)

Safety and effectiveness of gemcitabine for the treatment of classic Kaposi’s sarcoma without visceral involvement
por: Badalamenti, Giuseppe, et al.
Publicado: (2022)

Detection of RAS mutations in circulating tumor DNA: a new weapon in an old war against colorectal cancer. A systematic review of literature and meta-analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Analysis of tissue and circulating microRNA expression during metaplastic transformation of the esophagus
por: Cabibi, Daniela, et al.
Publicado: (2016)

Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome
por: Fanale, Daniele, et al.
Publicado: (2021)

The Emerging Therapeutic Landscape of ALK Inhibitors in Non-Small Cell Lung Cancer
por: Gristina, Valerio, et al.
Publicado: (2020)

Immunological Aspects of Von Hippel-Lindau Disease: A Focus on Neuro-Oncology and Myasthenia Gravis
por: Norata, Davide, et al.
Publicado: (2023)

How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis
por: Galvano, Antonio, et al.
Publicado: (2019)

Can circulating PD-1, PD-L1, BTN3A1, pan-BTN3As, BTN2A1 and BTLA levels enhance prognostic power of CA125 in patients with advanced high-grade serous ovarian cancer?
por: Fanale, Daniele, et al.
Publicado: (2022)

Can the microRNA expression profile help to identify novel targets for zoledronic acid in breast cancer?
por: Fanale, Daniele, et al.
Publicado: (2016)

“Back to a false normality”: new intriguing mechanisms of resistance to PARP inhibitors
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge
por: Bono, M., et al.
Publicado: (2021)

Type and Gene Location of KIT Mutations Predict Progression-Free Survival to First-Line Imatinib in Gastrointestinal Stromal Tumors: A Look into the Exon
por: Incorvaia, Lorena, et al.
Publicado: (2021)

The prognostic impact of tumor mutational burden (TMB) in the first-line management of advanced non-oncogene addicted non-small-cell lung cancer (NSCLC): a systematic review and meta-analysis of randomized controlled trials
por: Galvano, A., et al.
Publicado: (2021)

Analysis of systemic inflammatory biomarkers in neuroendocrine carcinomas of the lung: prognostic and predictive significance of NLR, LDH, ALI, and LIPI score
por: Galvano, Antonio, et al.
Publicado: (2020)

Low plasma PD-L1 levels, early tumor onset and absence of peritoneal carcinomatosis improve prognosis of women with advanced high-grade serous ovarian cancer
por: Fanale, Daniele, et al.
Publicado: (2023)

Beyond evidence-based data: scientific rationale and tumor behavior to drive sequential and personalized therapeutic strategies for the treatment of metastatic renal cell carcinoma
por: Incorvaia, Lorena, et al.
Publicado: (2016)

Denosumab for bone health in prostate and breast cancer patients receiving endocrine therapy? A systematic review and a meta-analysis of randomized trials
por: Galvano, Antonio, et al.
Publicado: (2019)

Body mass index and baseline platelet count as predictive factors in Merkel cell carcinoma patients treated with avelumab
por: Incorvaia, Lorena, et al.
Publicado: (2023)

Prognostic significance of circulating PD-1, PD-L1, pan-BTN3As, BTN3A1 and BTLA in patients with pancreatic adenocarcinoma
por: Bian, Benjamin, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_s8i2pec1m4hp5eg25u766ohr7v